Tags

Type your tag names separated by a space and hit enter

25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease.
Mov Disord. 2012 Feb; 27(2):264-71.MD

Abstract

We aimed to examine associations among serum 25-hydroxyvitamin D levels, 1,25-dihyroxyvitamin D levels, vitamin D receptor polymorphisms, vitamin D binding protein gene polymorphisms, and the severity of Parkinson's disease. In 137 patients, the severity of Parkinson's disease was evaluated using Hoehn & Yahr stage and Unified Parkinson's Disease Rating Stage by neurologists and compared with 25-hydroxyvitamin D, 1,25-hydroxyvitamin D, vitamin D receptor polymorphisms, ie, FokI (rs10735810), BsmI (rs1544410), Cdx2 (rs11568820), ApaI (rs7976091), and TaqI (rs731236), and vitamin D binding protein gene polymorphisms GC1 (rs7041)/GC2 (rs4588) in a cross-sectional study. Mean ± standard deviation levels of 25-hydroxyvitamin D were 21.1 ± 9.0 ng/mL. Levels were deficient (<20 ng/mL) in 49% of patients. In contrast, 1,25-hydroxyvitamin D levels were considered normal in all patients. Higher circulating 25-hydroxyvitamin D levels were significantly associated with milder Parkinson's disease evaluated by Hoehn & Yahr stage (P = .002) and total Unified Parkinson's Disease Rating Stage (P = .004) even after multivariate adjustment for 8 covariates, including disease duration. However, significant associations were not observed in 1,25-hydroxyvitamin D levels. Under multivariate analysis with 25-hydroxyvitamin D as well as other 8 covariates including disease duration, carriers of vitamin D receptor FokICC genotype had a milder form of Parkinson's disease: odds ratio, 0.32; 95% confidence interval, 0.16 to 0.66, P = 0.002. These results suggest that higher 25-hydroxyvitamin D levels and the vitamin D receptor FokICC genotype may be independently associated with milder forms of Parkinson's disease. However, significant associations were not observed in 1,25-hydroxyvitamin D levels.

Authors+Show Affiliations

Department of Neurology, Jikei University School of Medicine, Tokyo, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22213340

Citation

Suzuki, Masahiko, et al. "25-hydroxyvitamin D, Vitamin D Receptor Gene Polymorphisms, and Severity of Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 27, no. 2, 2012, pp. 264-71.
Suzuki M, Yoshioka M, Hashimoto M, et al. 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease. Mov Disord. 2012;27(2):264-71.
Suzuki, M., Yoshioka, M., Hashimoto, M., Murakami, M., Kawasaki, K., Noya, M., Takahashi, D., & Urashima, M. (2012). 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 27(2), 264-71. https://doi.org/10.1002/mds.24016
Suzuki M, et al. 25-hydroxyvitamin D, Vitamin D Receptor Gene Polymorphisms, and Severity of Parkinson's Disease. Mov Disord. 2012;27(2):264-71. PubMed PMID: 22213340.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease. AU - Suzuki,Masahiko, AU - Yoshioka,Masayuki, AU - Hashimoto,Masaya, AU - Murakami,Maiko, AU - Kawasaki,Keiichi, AU - Noya,Miki, AU - Takahashi,Daisuke, AU - Urashima,Mitsuyoshi, Y1 - 2011/12/31/ PY - 2011/06/10/received PY - 2011/09/17/revised PY - 2011/09/26/accepted PY - 2012/1/4/entrez PY - 2012/1/4/pubmed PY - 2012/6/15/medline SP - 264 EP - 71 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 27 IS - 2 N2 - We aimed to examine associations among serum 25-hydroxyvitamin D levels, 1,25-dihyroxyvitamin D levels, vitamin D receptor polymorphisms, vitamin D binding protein gene polymorphisms, and the severity of Parkinson's disease. In 137 patients, the severity of Parkinson's disease was evaluated using Hoehn & Yahr stage and Unified Parkinson's Disease Rating Stage by neurologists and compared with 25-hydroxyvitamin D, 1,25-hydroxyvitamin D, vitamin D receptor polymorphisms, ie, FokI (rs10735810), BsmI (rs1544410), Cdx2 (rs11568820), ApaI (rs7976091), and TaqI (rs731236), and vitamin D binding protein gene polymorphisms GC1 (rs7041)/GC2 (rs4588) in a cross-sectional study. Mean ± standard deviation levels of 25-hydroxyvitamin D were 21.1 ± 9.0 ng/mL. Levels were deficient (<20 ng/mL) in 49% of patients. In contrast, 1,25-hydroxyvitamin D levels were considered normal in all patients. Higher circulating 25-hydroxyvitamin D levels were significantly associated with milder Parkinson's disease evaluated by Hoehn & Yahr stage (P = .002) and total Unified Parkinson's Disease Rating Stage (P = .004) even after multivariate adjustment for 8 covariates, including disease duration. However, significant associations were not observed in 1,25-hydroxyvitamin D levels. Under multivariate analysis with 25-hydroxyvitamin D as well as other 8 covariates including disease duration, carriers of vitamin D receptor FokICC genotype had a milder form of Parkinson's disease: odds ratio, 0.32; 95% confidence interval, 0.16 to 0.66, P = 0.002. These results suggest that higher 25-hydroxyvitamin D levels and the vitamin D receptor FokICC genotype may be independently associated with milder forms of Parkinson's disease. However, significant associations were not observed in 1,25-hydroxyvitamin D levels. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/22213340/25_hydroxyvitamin_D_vitamin_D_receptor_gene_polymorphisms_and_severity_of_Parkinson's_disease_ L2 - https://doi.org/10.1002/mds.24016 DB - PRIME DP - Unbound Medicine ER -